1. Introduction
===============

The discovery of antibiotics has offered mankind a dramatically new approach to infection control and is considered as one of the milestones in medical history.^\[[@R1]\]^ A radical reduction in mortality and morbidity can be achieved in various infectious diseases. In the 1960s, some medical doctors including infectious disease specialists even declared "the end of the war against infectious diseases".^\[[@R2]\]^ However, bacteria have fought back aided by several evading strategies against antibiotics.^\[[@R3]\]^ At present, growing resistance of microorganisms diminishes the efficacy of existing antibiotics.^\[[@R4]\]^ Such ineffectiveness of antibiotics leads to increased mortality, morbidity, and medical costs.^\[[@R5]\]^

Increasing use of antibiotics is closely linked to the emergence of resistance due to enhancing selective pressure on bacteria.^\[[@R6]\]^ The key strategy to overcome the current problems caused by antimicrobial-resistant pathogens is implementation of antimicrobial stewardship programs (ASPs): a set of multidisciplinary activities focusing on the proper use of antimicrobials.^\[[@R7]\]^ In 2011, the World Health Organization (WHO) called on their national partners to take urgent action to realize ASPs,^\[[@R8]\]^ and the Korean Ministry of Health and Welfare emphasized the importance of ASPs in the recently established Korean national action plan on antimicrobial resistance in 2016.^\[[@R9]\]^

Monitoring antibiotic use and resistance patterns is the first step and one of the "core elements" for successful ASPs.^\[[@R10]\]^ Precisely measured data enables policy makers to establish proper measures for ASPs. The aim of this study is to evaluate the changing pattern of antibiotic usage and antimicrobial resistance of bacterial pathogens among hospitalized patients in Korea. We simultaneously investigated the correlation between antimicrobial resistance and antibiotic consumption.

2. Material and methods
=======================

2.1. Study design and setting
-----------------------------

We conducted a multicenter retrospective study at six hospitals located throughout the Korean peninsula (Fig. [1](#F1){ref-type="fig"}):

1.  Hanyang University Seoul Hospital \[858-bed, university-affiliated tertiary care hospital located in Seoul. It had 29-bed intensive care unit (ICU), 16-bed neonatal intensive care unit (NICU), and 10-bed bone marrow transplant unit (BMTU) in 2012. The patient-days for inpatients in 2012 was 237,805\];

2.  Gyeongsang National University Hospital (889-bed, university-affiliated tertiary care hospital located in Jinju. It has 27-bed ICU, 25-bed NICU, and 2-bed BMTU in 2012. The patient-days for inpatients in 2012 was 282,548);

3.  Korea University Ansan Hospital (543-bed, university-affiliated secondary care hospital located in Ansan. It has 36-bed ICU, 20-bed NICU, no BMTU in 2012. The patient-days for inpatients in 2012 was 187,967);

4.  Hanyang University Guri Hospital (578-bed, university-affiliated secondary care hospital located in Guri. It has 26-bed ICU, 7-bed NICU, and no BMTU in 2012. The patient-days for inpatients in 2012 was 170,656);

5.  Chonnam National University hospital (970-bed, university-affiliated tertiary care hospital located in Gwangju. It has 113-bed ICU, 28-bed NICU, and no BMTU in 2012. The patient-days for inpatients in 2012 was 327,278);

6.  Chungbuk National University hospital (620-bed, university-affiliated tertiary care hospital located in Cheongju. It has 29-bed ICU, 25-bed NICU, and no BMTU in 2012. The patient-days for inpatients in 2012 was 199,601).

![Geographic distribution of six hospitals in Korea.](medi-97-e13719-g001){#F1}

Data on total antibiotic prescriptions, patient days, and antimicrobial sensitivity tests were collected from inpatients at each hospital in 2004, 2008, and 2012. We blinded hospital\'s name in this article due to possibility of unintended blame on hospitals with higher rate of antibiotic use or antimicrobial resistance rate. The study protocol was approved by the Institutional Review Boards of the Hanyang University Hospital (2015-01-015), and the requirement for written informed consent from patients was waived due to the retrospective nature of the study, and its impracticability.

2.2. Definitions
----------------

### 2.2.1. Antibiotics

We defined antibiotics as medications with class J01 according to the Anatomical Therapeutic Chemical classification, which does not include antifungal or antituberculosis agents. Systemic agents with per oral or parenteral administration routes are included, while topical agents are excluded. We converted the amount of antibiotic consumption to defined daily dose (DDD) by using the Anatomical Therapeutic Chemical classification of WHO,^\[[@R11]\]^ and then standardized it for 1000 patient-days.

We classified antibiotic agents into 19 classes: first-generation cephalosporins (1st CEPs), second-generation cephalosporins (2nd CEPs), third-generation cephalosporins (3rd CEPs), fourth-generation cephalosporins (4th CEPs), aminoglycosides (AGs), beta-lactam/beta-lactamase inhibitors (BL/BLIs), carbapenems, fluoroquinolones (FQs), glycopeptides, lincosamide, macrolides, monobactam, metronidazole, oxazolidinone, penicillins, polymyxin, tetracycline, tigecycline, and trimethoprim/sulfmonamide (SXT). Other antibiotics such as amphenicol, fosfomycin, and streptogramin were excluded because they are rarely used.

We defined 3rd CEPs, 4th CEPs, BL/BLIs, and FQs as broad-spectrum antibiotics, and carbapenems, tigecycline, glycopeptides, oxazolidinone, and polymyxin as antibiotics against multidrug-resistant (MDR) pathogens. The other antibiotic classes were defined as non-broad-spectrum antibiotics.

### 2.2.2. Major bacterial pathogens and antimicrobial resistance

We analyzed antimicrobial sensitivity tests for major bacterial pathogens: *Escherichia coli*, *Klebsiella pneumoniae*, *Acinetobacter baumanii*, *Pseudomonas aeruginosa*, *and Staphylococcus aureus.* The first isolate of these pathogens for each month per patient was included for analysis. If there were 2 or more pathogens isolated from different sites, we chose according to the priority order. The priority order was as follows: cerebrospinal fluid, joint fluid, pleural fluid, ascites, blood, closed pus, urine, and sputum. Susceptibilities to antibiotics were determined by means of semi-automated systems at each hospital (VITEK, bioMèrieux, Hazelwood, MO, or Microscan, Dade Behring, West Sacramento, CA). The breakpoints of each compound were defined in reference to the Clinical and Laboratory Standards Institute,^\[[@R12]\]^ and R (resistance) or I (intermediate) were defined as resistance. We defined resistance against 3rd CEPs as resistance to at least one of the following antibiotics: cefotaxime, ceftriaxone, or ceftazidime.

2.3. Statistical analysis
-------------------------

The Jonckheere--Terpstra test using measures on a per-month basis was used to assess the trend of antibiotic consumption, proportion of pathogens, and antimicrobial resistance rate over time. We used the Kruskal--Wallis test to assess inter-hospital differences in antibiotic usage pattern and antimicrobial resistance. Pearson\'s correlation coefficient was used to describe the relationship between antibiotic consumption and bacterial resistance rates. Statistical significance was defined as *P* \<.05. All analyses were performed using SPSS 24.0 (IBM Corporation, Armonk, NY).

3. Results
==========

3.1. Overall consumption and trends of systemic antibiotic classes
------------------------------------------------------------------

The most commonly prescribed antibiotic subgroup was 3rd CEPs (24.8%, 213.82/862.94 DDD/1000 patient-days), followed by FQs (12.1%, 104.11/862.94 DDD/1000 patient-days), 2nd CEPs (11.4%, 98.17/862.94 DDD/1000 patient-days), 1st CEPs (10.6%, 91.84/862.94 DDD/1000 patient-days), and BL/BLIs (10.5%, 90.27/862.94 DDD/1000 patient-days) (Fig. [2](#F2){ref-type="fig"}). The proportion of broad-spectrum antibiotics, antibiotics against MDR pathogens, and non-broad-spectrum antibiotics use were 48.6% (419.88/862.93 DDD/1000 patient-days), 4.9% (41.95/862.93 DDD/1000 patient-days), and 46.5% (401.02/862.93 DDD/1000 patient-days), respectively.
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Table [1](#T1){ref-type="table"} presents the overall annual consumption of antimicrobial agents for systemic use. The mean antibiotic consumption was 862.93 DDD/1000 patient-days throughout the study period. Over the 9-year study period, a 15.1% decrease in total antibiotic consumption was observed in 2012 compared to that in 2004 (913.88 DDD/1000 patient-days in 2004; 874.34 DDD/1000 patient-days in 2008; 802.56 DDD/1000 patient-days in 2012, *P* \<.001). On comparing antibiotic consumption in 2012 with that in 2004, a 10.2% (394.10 DDD/1000 patient-days in 2004; 429.36 DDD/1000 patient-days in 2008; 434.44 DDD/1000 patient-days in 2012, *P* = .001) and 70.7% (29.77 DDD/1000 patient-days in 2004; 44.49 DDD/1000 patient-days in 2008; 50.83 DDD/1000 patient-days in 2012, *P* \<.001) increase in broad-spectrum antibiotics and antibiotics against MDR pathogens were observed, respectively. In comparison, a 34.7% decrease in non-broad-spectrum antibiotics (488.26 DDD/1000 patient-days in 2004; 401.26 DDD/1000 patient-days in 2008; 318.61 DDD/1000 patient-days in 2012, *P* \<.001) was observed.

###### 

Annual consumption of antimicrobial agents for systemic use at 6 hospitals in Korea, 2004 to 2012 (unit: DDD/1000 patient-days).
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3.2. Trend of antimicrobial resistance of bacterial pathogens
-------------------------------------------------------------

The proportion of bacterial pathogens commonly associated with antimicrobial resistance was 55.9%, and it had increased from 2004 to 2012 (*P* \<.001). The most frequently isolated pathogen among them was *S aureus* (15.5%), followed by *E coli* (13.8%) and *P aeruginosa* (15.5%). The proportions of *E coli* (13.5% in 2004; 12.6% in 2008; 15.4% in 2012, *P* = .009) had significantly increased from 2004 to 2012. The proportions of *K pneumoniae*, *A baumanii*, *P aeruginosa*, and *S aureus* remained stable throughout the study period (Table [2](#T2){ref-type="table"}).

###### 

Distribution of pathogens at 6 hospitals in Korea, 2004 to 2012 (unit: %).
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Table [3](#T3){ref-type="table"} presents the trend of antimicrobial resistance of bacterial pathogens. The resistance rate of *E coli* (from 17.6% in 2004 to 33.8% in 2012, *P* \<.001) and *K pneumoniae* (from 34.3% in 2004 to 44.5% in 2012, *P* \<.001) to 3rd CEPs showed a significantly increasing trend. Similarly, resistance of *E coli* to ciprofloxacin significantly increased (from 37.5% in 2004 to 46.6% in 2012, *P* = .001). In comparison, resistance of *K pneumoniae* to gentamicin significantly decreased throughout the study period (from 36.8% in 2004 to 26.4% in 2012, *P* = .019). The overall resistance rates of *E coli* and *K pneumoniae* to imipenem were lower than 0.01%. The resistance rate of *A baumanii* to ciprofloxacin (from 56.1% in 2004 to 71.9% in 2012, *P* = .020) and imipenem (from 8.9% in 2004 to 65.3% in 2012, *P* \<.001) increased over the study period. Resistance of *P aeruginosa* to cefepime (from 37.3% in 2004 to 29.8% in 2012, *P* = .028), ciprofloxacin (from 44.3% in 2004 to 34.5% in 2012, *P* \<.001), and gentamicin (from 44.3% in 2004 to 28.6% in 2012, *P* \<.001) appeared to be significantly decreasing. In contrast, resistance to imipenem significantly increased (from 25.1% in 2004 to 29.7% in 2012, *P* =.050). We observed that 76.4% *S aureus* was resistant to oxacillin and remained stable throughout the study period (*P* = .225). The resistance of *S aureus* to ciprofloxacin (from 66.5% in 2004 to 59.5% in 2012, *P* = .003) and gentamicin (from 71.9% in 2004 to 53.9% in 2012, *P* \<.001) demonstrated a significantly decreasing trend.

###### 

Trend of resistance to the indicated agent in bacterial pathogens commonly associated with antimicrobial resistance at 6 hospitals in Korea, 2004 to 2012.
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3.3. Correlations between antimicrobial resistance and antibiotic consumption
-----------------------------------------------------------------------------

The correlations between antimicrobial resistance and antibiotic consumption are summarized in Table [4](#T4){ref-type="table"}. The consumption of carbapenems and FQs demonstrated significant positive correlation for resistance of *E coli* or *K pneumoniae* to 3rd CEPs, while that to AGs demonstrated significant negative correlation. Similarly, for resistance of *E coli* or *K pneumoniae* to ciprofloxacin, the consumption of carbapenems and FQs demonstrated significant positive correlation, while that to AGs showed significant negative correlation. Increasing resistance of *A baumanii* to ciprofloxacin was observed during the study period and was significantly correlated with increasing consumption of FQs. Similarly, increasing resistance of *A baumanii* to imipenem was significantly correlated with increasing consumption of carbapenems. For *P aeruginosa*, the decreasing consumption of AGs significantly correlated with decreasing resistance rate to gentamicin. In comparison, the consumption of FQs demonstrated negative correlation with *P aeruginosa* resistance to ciprofloxacin. The resistance of *S aureus* to oxacillin demonstrated a significant positive correlation with the consumption of glycopeptides.

###### 

Correlations between antimicrobial resistance and antibiotic consumption at 6 hospitals in Korea.
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3.4. Inter-hospital difference in antibiotic usage pattern and antimicrobial resistance
---------------------------------------------------------------------------------------

Hospital F consumed highest amount of broad-spectrum antibiotics, while hospital C consumed them least among the 6 hospitals (41.2% in hospital A; 54.1% in hospital B; 40.4% in hospital C; 42.6% in hospital D; 51.7% in hospital E; 58.7% in hospital F, *P* = .046). In comparison, there were no significant differences in the consumption of antibiotics against MDR pathogens (3.1% in hospital A; 5.2% in hospital B; 5.4% in hospital C; 3.5% in hospital D; 5.3% in hospital E; 7.0% in hospital F, *P* = .472) and non-broad-spectrum antibiotics (55.6% in hospital A; 40.7% in hospital B; 54.2% in hospital C; 53.9% in hospital D; 42.9% in hospital E; 34.3% in hospital F, *P* = .088) among the 6 hospitals. When compared according to antibiotic classes, 3rd CEPs (*P* = .020), FQs (*P* = .048), 1st CEPs (*P* = .010), lincosamide (*P* = .016), tetracycline (*P* = .029), and SXT (*P* = .050) demonstrated significant differences among the hospitals (Supplement 1).

The resistance rate of *K pneumoniae* to 3rd CEPs and ciprofloxacin demonstrated significant difference among hospitals, ranging from 16.7% to 50.0% and 19.4% to 48.0%, respectively (*P* = .038 and .035, respectively). Antimicrobial resistance of *E coli*, *A baumanii*, *P aeruginosa*, and *S aureus* did not significantly differ among hospitals (Supplement 2).

4. Discussion
=============

The present study reflects the current status of antibiotic usage and antimicrobial resistance patterns at the hospital level in Korea. We believe that our findings can be useful for implementation of antimicrobial stewardship policies.

Most frequently prescribed antibiotics for inpatients were cephalosporins, FQs, and BL/BLIs, comprising 69.4% of the total antibiotic consumption. We noted that the antibiotic prescription patterns vary according to hospital type and size. Bitterman et al observed that antibiotic consumption was higher in teaching or public hospitals than other acute care hospitals.^\[[@R13]\]^ Similarly, the antibiotic prescription patterns differ between referral hospitals and smaller hospitals in Korea.^\[[@R14]\]^ Such differences may arise from differences in patient groups. Generally, patients in referral hospitals have more severe problems and/or underlying diseases compared those in smaller hospitals.

Although all 6 hospitals in our study are in similar settings, there were significant differences in the proportion of broad-spectrum antibiotics among hospitals, especially, 3rd CEPs and FQs. Interestingly, the inter-hospital differences in antimicrobial resistance may not influence the differences in antibiotic usage pattern. On examining the resistance of *K pneumoniae* to ciprofloxacin, which showed a statistically significant difference among hospitals, the resistance rate of hospital B was the lowest but the consumption of FQs was the highest. Similarly, resistance of *K pneumoniae* to 3rd CEPs was the second highest in hospital A but the consumption of 3rd CEPs was the second lowest. This indicates that other factors may influence antibiotic usage pattern in a hospital. We suggest that behavioral factors, such as physician\'s attitude and knowledge, may play an important role in influencing these patterns. A Korean study reported that lack of knowledge is one of the main factors responsible for inappropriate antibiotic use in university hospitals.^\[[@R15]\]^ Therefore, the medical staff should be properly educated, and prompt feedback regarding inappropriate antibiotic usage should be mandatory to achieve antimicrobial stewardship. Some authors suggested that providing feedback letters or peer group interventions can also be useful strategies.^\[[@R16],[@R17]\]^

In the present study, there was steady increase in the proportion of Enterobacteriaceae resistant to 3rd CEPs or ciprofloxacin. According to the Korean Antimicrobial Resistance Monitoring System (KARMS), involving a total of 35 secondary and tertiary hospitals, the resistance rate of *E coli* to cefotaxime and FQs increased from 10% in 2004 to 29% in 2013 and from 30% in 2004 to 42% in 2013, respectively.^\[[@R18]\]^ Similarly, the resistance rate of *K pneumoniae* to cefotaxime and FQs increased from 30% in 2004 to 40% in 2013 and from 30% in 2004 to 34% in 2013, respectively.^\[[@R18]\]^ Another notable finding is that the resistance rate of *A baumanii* to imipenem was the largest during the study period. Similar results were observed in the study by KARMS: the resistance increased from 18% in 2004 to 77% in 2013.^\[[@R18]\]^ Another nationwide surveillance system, the Korean Nosocomial Infection Surveillance System, reported that imipenem-resistant *A baumanii* increased from 52.9% in 2006 to 89.8% in 2013 (*P* \<.0001) in ICUs in Korea.^\[[@R19]\]^ Interestingly, the resistance rate of *P aeruginosa* to gentamicin seems to be decreasing over time, which is concordant to the finding from KARMS.^\[[@R18]\]^ Considering the resistance rate of *E coli, K pneumoniae*, and *P aeruginosa* to gentamicin was lower than to ciprofloxacin, AGs could be an option for the treatment of infections caused by MDR gram-negative pathogens in Korean hospitals.

The increasing antimicrobial resistance may partially explain the increasing consumption of broad-spectrum antibiotics and antibiotics against MDR pathogens. The result of the correlation between antibiotic consumption and antimicrobial resistance support this explanation. Increasing carbapenem consumption may have resulted from the increasing resistance of *E coli* to 3rd CEPs and ciprofloxacin, as well as increasing resistance of *K pneumoniae* to 3rd CEPs. In addition, an increasing proportion of oxacillin-resistant *S aureus* may have resulted in the increasing consumption of glycopeptide.

Antimicrobial resistance and antibiotic consumption influences each other. Antimicrobial resistance may influence the physician\'s antibiotic prescription, similar to how antibiotic consumption may increase selective pressure on certain classes of antibiotics in pathogens. Consistent with previous studies, the consumption of FQs may have caused the emergence of 3rd CEP-resistant *E coli* and *K pneumoniae*, as well as ciprofloxacin-resistant *E coli* and *K pneumoniae.*^\[[@R20]--[@R22]\]^ Furthermore, the consumption of carbapenems may have increased resistance of *A baumanii* to imipenem.^\[[@R22]\]^ However, we could not determine the protective effect of BL/BLIs against the emergence of 3rd CEPs-resistant *E coli*, as demonstrated in an Italian study.^\[[@R23]\]^ Moreover, in contrast to a previous study, negative correlation between the consumption of FQs and ciprofloxacin-resistant *P aeruginosa* was demonstrated in our study.^\[[@R22]\]^ The correlation between antibiotic prescription and the resistance rate in gram-negative bacteria has been reported as a non-uniform relationship in different studies.^\[[@R20]\]^ We suggest that further studies are needed to investigate this in detail.

Our study has some limitations. First, the present study was conducted in university hospitals, and many of the patients had underlying illnesses. Therefore, the antimicrobial resistance rate and antibiotic consumption could be overestimated. Second, we analyzed the correlation between antibiotic consumption and antimicrobial resistance regardless of other factors. Even if statistically significant, the consumption of certain antibiotic drugs may not be directly correlated with antimicrobial resistance. Third, antibiotic susceptibility test was not conducted in a single center and the antibiotics tested for susceptibility varied among institutions. Therefore, we only could analyze resistance to a limited number of antibiotics. Finally, antibiotic consumption was measured by DDD instead of days of therapy (DOT). Although DDD has disadvantages in pediatrics and patients with chronic kidney disease,^\[[@R24]\]^ we could not utilize DOT because only the total amount of antibiotic consumption for each identification number was available in most hospitals.

5. Conclusions
==============

Nonetheless, the overall data in the present study may be a reasonable indicator of antibiotic usage and resistance pattern among hospitalized patients in Korea. In conclusion, overall antimicrobial resistance increased and consumption of broad-spectrum antibiotics and antibiotics against MDR pathogens subsequently increased in Korean hospitals. Proper ASPs in each hospital are mandatory to overcome the potential threats by MDR pathogens.
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